NIP
MDGL icon

Nicholas Investment Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Nicholas Investment Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,025
Closed -$1.07M – 236
2024
Q3 		$1.07M Buy
+5,025
New +$1.29M 0.1% 180
2023
Q2 		– Sell
-117,047
Closed -$28.4M – 204
2023
Q1 		$28.4M Buy
+117,047
New +$31.9M 2.16% 8

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nicholas Investment Partners's MDGL Position: Q4 2024 in Review

Nicholas Investment Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 5,025 shares — an estimated $1.07M sold.

Nicholas Investment Partners first reported a position in MDGL in Q1 2023 and held it in 2 quarters. The position peaked at $28.4M in Q1 2023. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

  • Nicholas Investment Partners reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 5,025 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $1.07M.
  • Nicholas Investment Partners first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Nicholas Investment Partners's Madrigal Pharmaceuticals position peaked at $28.4M in Q1 2023.
  • 283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on Nicholas Investment Partners's 13F filing for Q4 2024, filed 14 Feb 2025.